Orion Oyj: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Thomson Reuters StreetEvents
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Orion Oyj Confirms FY 2013 Guidance
Orion Oyj announced that its outlook estimate for the fiscal year 2013 remains unchanged. Orion estimates that in the fiscal year 2013, net sales (revenue) will be at similar level to 2012 and that operating profit (EBIT) will be slightly lower than in 2012. For the fiscal year 2012, the Company reported revenue of EUR 980.40 million and EBIT of EUR 280.90 million. According to I/B/E/S Estimates, analysts on average are expecting the Company to report revenue of EUR 981.68 million and EBIT of EUR 262.30 million for the fiscal year 2013.
Latest Developments for Orion Oyj
- Orion Oyj comments on outlook estimate for FY 2014
- Orion Oyj enter into global partnership with Bayer for development and commercialization of ODM-201compound; upgrades FY 2014 outlook
- Orion maintains FY 2014 financial guidance
- Orion Oyj receives Irish and Hungarian marketing authorizations for Bufomix Easyhaler product
Latest Key Developments in Pharmaceuticals
- Share this
- Digg this